{"commentary":{"count":88,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":67,"youtube":12,"podcast":8,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05925530\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MDT-BRIDGE","nct_id":"NCT05925530","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mdt-bridge-nct05925530. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"MDT-BRIDGE","arms":[{"description":"Durvalumab will be administered to the participants via intravenous infusion (IV)","label":"Durvalumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08-27","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":142,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"AstraZeneca","official_title":"A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Resection rate","timeFrame":"At day of surgery (Within 40 days of the last dose of neoadjuvant treatment)"}],"references":[],"start_date":{"date":"2024-02-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","url":"https://clinicaltrials.gov/study/NCT05925530"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mdt-bridge-nct05925530"}